01 1Curia
01 1NOREPINEPHRINE BITARTRATE, USP
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2015-12-23
Pay. Date : 2015-07-23
DMF Number : 29562
Submission : 2015-07-31
Status : Active
Type : II
20
Curia New York Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
They are recognized for Curia- A partner for the pharma and biotech industries to improve patient outcomes & quality of life.
One of their notable products is NOREPINEPHRINE BITARTRATE, USP, with a corresponding US DMF Number 29562.
Remarkably, this DMF maintains an Active status since its submission on July 31, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of December 23, 2015, and payment made on July 23, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II
